skip to main content

BRIN-BD11

BRIN-BD11

Catalogue No.

10033003

Cell Line Name

BRIN-BD11

Cell Line Description

BRIN-BD11 is a hybrid cell line formed by the electrofusion of a primary culture of NEDH rat pancreatic islets with RINm5F (a cell line derived from a NEDH rat insuliinoma). BRIN-BD11 has been shown to be tumourigenic when transplanted into a SCID mouse host. BRIN-BD11 has been mycoplasma eradicated at ECACC and the stocks available for supply have undergone a further 10 passages without detection of mycoplasma. The cell line has applications in the study of pancreatic beta cell function.

General Info

Species

Rat

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

Not specified

Products

BRIN-BD11 is a stable, glucose-responsive insulin secreting beta cell line expressing insulin, glucokinase and IAPP as detected by immunocytochemistry. BRIN-BD11 cells express the GLUT2 glucose transporter.

Tissue of Origin

Pancreatic islets

Karyotype

Modal chromosome number 58 over 50 passages

Disease

None Stated

Culture Conditions

Cell Type

Epitheloid

Subculture Routine

Split sub-confluent cultures (70-80%) 1:8 to 1:10 i.e. seeding at 2-4 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Population doubling approx 20hrs. At confluence 10⁵ cells/cm² can be expected.

Culture Medium

RPMI-1640 + 2mM Glutamine + 10% FCS

Growth Mode

Adherent

Additional Info

Depositor

Professor Peter R Flatt, Head of Diabetes Research Group, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Northern Ireland BT52 1SA.

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW, Swanston-Flatt SK, Flatt PR. 1996 Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion Diabetes. 45(8):1132-40. PMID: 8690162

Bibliography

McClenaghan NH, Flatt PR 1999 Engineering cultured insulin-secreting pancreatic B-cell lines. J Mol Med. 77(1):235-43 PMID: 9930971.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: BRIN-BD11 (ECACC 10033003).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.